ReviewSeminars in cancer biology2009
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.
Review in Seminars in cancer biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Metabolic Reprogramming Shapes the Progression and Therapeutic Landscape of Ovarian Cancer.Cancer management and research · 2025Review
- Research Progress of CXCR4-Targeting Radioligands for Oncologic Imaging.Korean journal of radiology · 2023Review
- Identification of novel biomarkers of prostate cancer through integrated analysis.Translational andrology and urology · 2021Article
- Article
- Genetic variants associated with colorectal brain metastases susceptibility and survival.The pharmacogenomics journal · 2017Article
- Tumor talk: understanding the conversation between the tumor and its microenvironment.Cancer cell & microenvironment · 2015Article
- β-Arrestin1 and distinct CXCR4 structures are required for stromal derived factor-1 to downregulate CXCR4 cell-surface levels in neuroblastoma.Molecular pharmacology · 2014Article
- Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.PloS one · 2013Article
- Development of a unique small molecule modulator of CXCR4.PloS one · 2012Article
- Current molecular imaging positron emitting radiotracers in oncology.Nuclear medicine and molecular imaging · 2011Review
- ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.Biochimica et biophysica acta · 2009Review
- Chemokines and the microenvironment in neuroectodermal tumor-host interaction.Seminars in cancer biology · 2009Review
- Molecular cloning, characterization, and expression analysis of the CXCR4 gene from Turbot: Scophthalmus maximus.Journal of biomedicine & biotechnology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Chemokines (chemotactic cytokines) are a family of proteins associated with the trafficking and activation of leukocytes and other cell types in immune surveillance and inflammatory response. Besides their roles in the immune system, they play pleiotropic roles in tumor initiation, promotion, and progression. Chemokines can be classified into four subfamilies of chemokines, CXC, CC, C, or CX3C, based on their number and spacing of conserved cysteine residues near the N-terminus. This CXC subfamily can be further subclassified into two groups, depending on the presence or absence of a tripeptide motif glutamic acid-leucine-arginine (ELR) in the N-terminal domain. ELR(-)CXCL12, which binds to CXCR4 has been frequently implicated in various cancers. Over the past several years, studies have increasingly shown that the CXCR4/CXCL12 axis plays critical roles in tumor progression, such as invasion, angiogenesis, survival, homing to metastatic sites. This review focuses on involvement of CXCR4/CXCL12 interaction in neuroectodermal cancers and their therapeutic potentials. As an attractive therapeutic target of CXCR4/CXCL12 axis for cancer chemotherapy, development history and application of CXCR4 antagonists are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.